Delek US Completes Sale of Retail Related Assets for $535 million
Nov 14, 2016 21:25 pm UTC| Business
BRENTWOOD, Tenn., Nov. 14, 2016 -- Delek US Holdings, Inc. (NYSE:DK) (“Delek”) has closed the previously announced transaction to sell its retail related assets to a U.S. subsidiary of Compañía de Petróleos de Chile...
Salon Media Group Reports Second Quarter Fiscal 2017 Results
Nov 14, 2016 21:24 pm UTC| Business
NEW YORK, Nov. 14, 2016 -- Salon Media Group, Inc. (OTCQB:SLNM) today announced its results for the three and six months ending September 30, 2016. Highlights: Transition from direct...
Energy XXI Enters Into Comprehensive Plan Support Agreement With Key Creditor Groups
Nov 14, 2016 21:21 pm UTC| Business
HOUSTON, Nov. 14, 2016 -- Energy XXI Ltd (OTC:EXXIQ) (“Energy XXI” or the “Company”) today announced that it has entered into a plan support agreement (the “plan support agreement”) with substantially all of the...
CurAegis Technologies, Inc. Issues CEO Product Update
Nov 14, 2016 21:18 pm UTC| Business
ROCHESTER, N.Y., Nov. 14, 2016 -- On November 14, 2016, Richard A. Kaplan, the chief executive officer of CurAegis Technologies, Inc., provided the following update of the Company’s accomplishments and business...
INC Research to Present at Upcoming Nasdaq Investor Conference
Nov 14, 2016 21:16 pm UTC| Business
RALEIGH, N.C., Nov. 14, 2016 -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to Phase IV contract research organization, today announced that Chief Executive Officer Alistair Macdonald is...
Nasdaq Names Adena Friedman Chief Executive Officer
Nov 14, 2016 21:15 pm UTC| Business
NEW YORK, Nov. 14, 2016 -- Nasdaq is today announcing its Board of Directors has named Adena Friedman President and Chief Executive Officer, and she will also join the Board of Directors, effective January 1, 2017. ...
Nov 14, 2016 21:15 pm UTC| Business
NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., Nov. 14, 2016 -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced results from three substudies of the pivotal Phase 3 APEX Study of betrixaban, an oral,...